Canada markets closed

KetamineOne Capital Limited (MEDI.NE)

NEO - NEO Real Time Price. Currency in CAD
Add to watchlist
0.48000.0000 (0.00%)
At close: 12:23PM EDT
Sign in to post a message.
  • p
    partystocker
    KetamineOne Capital $MEDI has seen some downward price action the last few months, but I think this is more due to general public apprehension towards the therapeutic psychedelic field than anything else.

    We’re currently seeing more news pick up this industry in a positive light, and conferences/events promoting the therapeutic psychedelic industry are also seeing more interest and turnout.

    The use of ketamine as a therapy is continuing to be studied and progressed, and KetamineOne is one of the companies leading the way with clinical trials to perfect the administration and usage of the drug.

    Given that this industry is in its fledgling stages, huge moves aren’t to be expected too soon. But once ketamine usage for treatment is openly and widely accepted, insured, and has passed government approvals, theres tons of room for the company's currently trading in penny markets to see some real growth.

    I’m staying optimistic about the industry and keeping an eye on KetamineOne. MEDI.NEO currently trading at $.50 and valued at $60.08M
  • W
    Waves
    I'm really looking forward to the results of KetamineOne ($MEDI $MEDI.ne $KONEF)'s research study in association with Biostrap!

    The data derived from the study will be analyzed with the aim of identifying biometric signatures that arise over the course of the treatments and will aid in making dosage and timing decisions to reduce the chance of relapse.

    Being a data-driven organization will give $MEDI a solid competitive advantage as it enables them to produce better treatment outcomes.

    https://finance.yahoo.com/news/ketamine-one-features-biostrap-part-070000110.html
    The Observational Studies Will Collect Advanced Biometric Data in Upcoming Depression and PTSD StudiesVANCOUVER, British Columbia, Oct. 20, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF
    The Observational Studies Will Collect Advanced Biometric Data in Upcoming Depression and PTSD StudiesVANCOUVER, British Columbia, Oct. 20, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF
    finance.yahoo.com
  • W
    Waves
    Exciting news for KetamineOne ($MEDI $MEDI.ne)!

    $MEDI recently announced that its contract research organization, KGK Science Inc, has been contracted by a third party to work on a new ketamine trial in the USA!

    Highlights:
    - KGK's engagement is related to a ketamine clinic trial
    - The third party is a provider of digital therapeutics or the psychedelic and mental health sectors
    - The third-party will be one of the first companies to collect data points and understand how ketamine can resolve issues in the brain.

    This is massive for both $MEDI and their contract research organization KGK, it is an insanely promising trial.

    You can read more here:
    https://www.ketamine.one/releases/ketamine-one-subsidiary-kgk-science-contracted-to-support-a-ketamine-clinical-trial-in-the-united-states
    Ketamine One Subsidiary KGK Science Contracted To Support A Ketamine Clinical Trial In The United States
    www.ketamine.one
  • p
    partystocker
    Mental health, despite its commonality, still has so much stigma attached to it.

    That's why I am really rooting for $MEDI rn- they're destigmatizing mental illness and the use drugs for treatment, and making amazing progress along the way.

    20% of Americans are documented to be living with mental illness, but i predict that number to be even higher. Almost 9% experience PTSD, and over 20m are addicted to substances- and nearly none of them receive treatment.

    $MEDI.NEO was created to provide mental wellness care through ketamine-enhanced treatments. They have 15 clinics already w 4 more on the way, and they're dedicated to giving people an opportunity to cure their mental illness and disease with the use of psychedelics.

    Breaking barriers, breaking boundaries, and ultimately, helping people- def one of my top picks in the psychedelic industry rn.

    up at $.60 td, MC $72.09M
  • S
    StockHawk
    $MEDI.N / $KONEF confirms that they will be conducting a study in partnership with Biostrap to use wearable tech to collect biological data from depression and PTSD patients while they receive ketamine treatment.

    $MEDI dropped 10% out of no wear today meaning that it is trading @ just $0.465/share. Today could be a great opportunity to invest in them on the cheap. MC is $55.87 M.

    https://finance.yahoo.com/news/ketamine-one-features-biostrap-part-070000110.html
    The Observational Studies Will Collect Advanced Biometric Data in Upcoming Depression and PTSD StudiesVANCOUVER, British Columbia, Oct. 20, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF
    The Observational Studies Will Collect Advanced Biometric Data in Upcoming Depression and PTSD StudiesVANCOUVER, British Columbia, Oct. 20, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF
    finance.yahoo.com
  • S
    StockHawk
    KetamineOne ( $MEDI.N $KONEF ) announced earlier this month that they have entered into an agreement with Psychology & Counselling Services Group to provide mental health services for $MEDI

    This partnership will begin as early as October of this year.

    They also announced that they will be opening a special clinic in partnership with Veterans Services to treat veterans with PTSD and other trauma-related disorders.

    Overall September seems to have been a really good month for $MEDI, so I was a little surprised to see that their stock price dropped about 5% today. Any thoughts on why this might be?

    For those invested would you say it is a good time to stock up while its taken this dip?

    Currently $MEDI.N is selling for $1.09/share, MC is $130.58M

    https://www.ketamine.one/releases/ketamine-one-engages-psychology-counselling-services-group-for-irp-health-pcsg-to-provide-psychology-therapy-dietary-and-other-mental-health-services-for-the-wholly-owned-ketamine-one-subsidiary
    Ketamine One Engages Psychology & Counselling Services Group for IRP Health PCSG to Provide Psychology, Therapy, Dietary and Other Mental Health Services for the Wholly-Owned Ketamine One Subsidiary
    www.ketamine.one
  • H
    Henry
    KetamineOne announces single arm, open-label study of PTSD patients in PT programs at $MEDI IRP health clinics & pilot study in patients receiving IV ketamine infusion therapies treating depression. Solid news driving wider applications for $KONEF therapies! https://bit.ly/3oZCeHC
  • S
    StockHawk
    Big news for KetamineOne Capital Limited ( $MEDI.N $KONEF)!

    Yesterday the mental health clinics and treatment company announced that they will launch a study of PTSD patients who are participating in therapy at their IRP Health clinics.

    Additionally, $MEDI is also conducting a pilot study aimed at collecting objective biometric data and psychiatric measures of efficacy for depressed patients who are receiving IV ketamine infusion therapy at their clinics.

    Both of these studies will be conducted in multiple Ketamine One clinics across Canada and the USA and are expected to begin in November.

    It is great to see that $MEDI is not only adding to the scientific community but also continuing to validate their own treatments' efficacy.

    $MEDI @ $0.58, MC $69.69 M

    For more info on the details of both studies read here:
    https://www.globenewswire.com/news-release/2021/10/14/2313950/0/en/Ketamine-One-Launching-Two-Inaugural-Research-Studies.html
    The Single-Arm Studies Will Be Focused on Treatment-Resistant Depression and Post-Traumatic Stress Disorder...
    The Single-Arm Studies Will Be Focused on Treatment-Resistant Depression and Post-Traumatic Stress Disorder...
    www.globenewswire.com
  • L
    Lucas
    $MEDI looking extremely undervalued and like a great opportunity IMO.

    They recently announced their wholly owned subsidiary KGK Science has been contracted by a third party to develop the protocol and Informed Consent Form to support its Institutional Review Board application to assist with a ketamine clinical trial that is being planned to be conducted by a clinic operator.

    The purpose of the study will be to obtain objective data to support the belief that the proper dosing and administration of intravenous Ketamine treatments can result in neuroplasticity and sustainable relief from depression, with or without PTSD.

    Sitting very cheap rn at 59c and with their focus on destigmatizing mental health, I think $MEDI is a great way to get into the ketamine market.

    https://www.ketamine.one/releases/ketamine-one-subsidiary-kgk-science-contracted-to-support-a-ketamine-clinical-trial-in-the-united-states
    Ketamine One Subsidiary KGK Science Contracted To Support A Ketamine Clinical Trial In The United States
    www.ketamine.one
  • T
    Tory
    $MEDI is a really spectacular company ! even if you don’t invest in the psychedelic / wellness sector $MEDI is worth checking out.

    They recently announced they have received support to run ketamine clinical trials in Miami, Florida.

    Ketamine treatment aims to resolve issues in the brain, like depression, addiction, and PTSD through a process called neuroplasticity. The study will be to obtain supporting information of that believe that proper dosing and administration of ketamine through “IV” can result in neuroplasticity, providing sustainable relief from the aforementioned mental illnesses.

    Neuroplasticity is an umbrella term that can be interpreted as the “brains ability to modify, change, and adapt both structure and function throughout life and in response to experience.”

    Regardless of if you are investing or not its great to see clinics like this opening up. Providing relief from various mental illnesses that had been previously treated through prescription medication or other long term, sometimes, less effective treatments.

    $MEDI at $0.57 a share with a market cap of 58.91M

    https://www.ketamine.one/releases/ketamine-one-subsidiary-kgk-science-contracted-to-support-a-ketamine-clinical-trial-in-the-united-states
    Ketamine One Subsidiary KGK Science Contracted To Support A Ketamine Clinical Trial In The United States
    www.ketamine.one
  • A
    Alex
    $MEDI @ $1.30 , market cap $155.09 M

    $KONEF

    Love that $MEDI.N is involved in high-quality digital combination therapies- the incorporation of digital therapeutics have the potential to improve safety and effectiveness of many different treatments

    implementing digital therapeutic in a clinical environment is also a pivotal step towards developing scalable care

    https://www.psychedelicfinance.com/articles/atai-life-sciences-and-introspect-digital-therapeutics-to-test-novel-digital-therapeutic-approach-in-patients-receiving-ketamine-for-treatment-resistant-depression

    It’s a very exciting time for companies like $MEDI.

    More and more research is coming out on the therapeutic benefits of ketamine - from Treatment resistant depression to ALS . Last month the FDA granted PharmaTher orphan drug designation of ketamine for the treatment of Lou Gehrig’s disease.
  • W
    Waves
    The FDA recently green-lit the use of ketamine for ALS treatments, and by doing so, recognized the medically plausible basis for ketamine to be used for treatment.

    This recognition is massive for KetamineOne ($MEDI $MEDI.ne) as it:
    - Validates the benefits of ketamine assisted therapy
    - Helps develop and commercialize ketamine assisted therapy
    - Validates the belief in the potential of ketamine as a therapeutic solution for neurological disorders.
    https://psychedelicspotlight.com/fda-green-lights-ketamine-treatment-als/
    By granting this status to psychedelics biotechnology company PharmaTher, the FDA recognizes medically plausible basis for ketamine treatment.
    By granting this status to psychedelics biotechnology company PharmaTher, the FDA recognizes medically plausible basis for ketamine treatment.
    psychedelicspotlight.com
  • S
    StockHawk
    Ketamine One $MEDI.N $KONEF is a Ketamine therapy company with clinics across North America.

    Today they announced that they signed a letter of interest with Veteran Services USA to lease approximately 5K square feet of space in a Veteran Services facility in Blue Island, Illinois.

    $MEDI is planning on using the Blue Island Therapy Center to innovate ketamine-assisted therapies for veterans suffering from PTSD and other trauma-related issues.

    Additionally $MEDI will be working with Veteran Services to find more locations they can use within the Veteran Services network.

    This move will not only allow $MEDI to expand their clinics but also facilitates their treatments being brought to Veterans, who arguably need it the most.

    Full article here: https://www.ketamine.one/releases/ketamine-one-signs-loi-with-veteran-services-usa-to-open-therapy-center
    Ketamine One Signs LOI with Veteran Services USA to Open Therapy Center
    www.ketamine.one
  • M
    Matty
    With the global digital therapeutics market expected to reach USD $13.8B by 2027, growing at a CAGR of 20.5%, I'm looking forward to see what the future holds for $MEDI's digital therapeutic initiatives. Just announced agreement with Cognetivity, a tech company, for their Integrated Cognitive Assessment to be deployed in Ketamine One's clinics across North America!
  • S
    StockHawk
    Ketamine One $MEDI.N $KONEF is a Ketamine-assisted therapy company

    $MEDI has clinics across North America, and pursuant on an LOI they signed with Veteran Services USA they will be opening another clinic especially for Veterans with PTSD and other trauma related mental conditions

    $MEDI also indicated that they are planning on opening additional clinics with Veteran Services.

    This is a huge move for $MEDI that will both expand their clinical presence in the US while delivering their therapies to those who need it most.
    https://www.ketamine.one/releases/ketamine-one-signs-loi-with-veteran-services-usa-to-open-therapy-center

    $MEDI is trading at $1.30 , MC $155 Million
    Ketamine One Signs LOI with Veteran Services USA to Open Therapy Center
    www.ketamine.one
  • S
    StockHawk
    Found this trendhunter article on KetamineOne ( $MEDI.n $KONEF ) and OVR Tech.'s INHALE Wellness Platform

    INHALE is a scent-enabled VR platform.

    When using this therapeutic technology, triggering scents are paired with VR experiences to stimulate memories

    It is great to see $MEDI collaborating with other companies and pushing themselves to make their therapeutic techniques as best as they can possibly be. As some who has studied a lot of psychology I think this scent technology could make huge waves in the therapeutic field.

    MC $160.94 M

    https://www.trendhunter.com/trends/ketamin-one
    Ketamin One - Health and wellness company Ketamine One has partnered with OVR Technology, a company specializing in therapeutic virtual reality solutions. The pa...
    Ketamin One - Health and wellness company Ketamine One has partnered with OVR Technology, a company specializing in therapeutic virtual reality solutions. The pa...
    www.trendhunter.com
  • J
    Jordan
    Lots of interesting stuff here. Rapid expansion both clinically and technically. Only a matter of time before the SP reflects the business growth! Tech integration is second to none.
  • J
    Jordan
    $MEDI has the largest clinical network among all their major competitors. Plus, they not only have a tremendous clinical footprint, but they also have a top-notch cutting-edge research program. More growth and revenues to come. Honestly, we just need a bit more recognition and volume then we're golden!
  • L
    Luke
    $MEDI $MEDI.NE just announced that it has recently entered into a non-binding LOI to enter into an arranged partnership with Illumma LLC.

    Illumma is a leading ketamine infusion practice that currently has 2 clinics in Texas. Under the arrangement, Illumma’s 2 locations would be jointly supported alongside the company’s existing network of clinics across North America, thereby raising the profile of $MEDI ‘s innovative mental health platform and approach to patient care in the United States.

    On a slower day it’s great to see $MEDI get into the US which will significantly grow their offering of clinics to prospective patients in the United States.

    https://www.ketamine.one/releases/ketamine-one-signs-loi-for-two-ketamine-infusion-clinics-in-texas
    Ketamine One Signs LOI for Two Ketamine Infusion Clinics in Texas
    www.ketamine.one
  • A
    Alex
    $MEDI @ $1.45

    They just announced their agreement with Cognetivity to deploy their Integrated Cognitive Assessment (ICA) in $MEDI.N clinics across North America

    https://www.ketamine.one/releases/ketamine-one-to-deploy-cognetivitys-integrated-cognitive-assessment-tool

    Cognetivity’s ICA AI powered and highly sensitive to small changes in cognitive performance and as opposed to traditional paper-based surveys will grant MEDI bettie all around cognitive testing: more accurate, standardized, more efficient and unbiased.

    Observing cognitive changes over the course of patients treatment will enable measurement of treatment efficacy and generate additional data to improve $MEDI treatments.

    Stoked but not surprised to see MEDI innovating their practices yet again with digital therapeutics. 

    Estimated addressable market size for anxiety disorder and depression treatments is US$238 billion.

    $MEDI
    market cap $ 172.86 M
    Ketamine One to Deploy Cognetivity’s Integrated Cognitive Assessment Tool
    www.ketamine.one